PMID- 32383250
OWN - NLM
STAT- MEDLINE
DCOM- 20210510
LR  - 20210510
IS  - 2192-2659 (Electronic)
IS  - 2192-2640 (Linking)
VI  - 9
IP  - 12
DP  - 2020 Jun
TI  - The Progress and Prospect of Zeolitic Imidazolate Frameworks in Cancer Therapy, 
      Antibacterial Activity, and Biomineralization.
PG  - e2000248
LID - 10.1002/adhm.202000248 [doi]
AB  - The progressive development of zeolitic imidazolate frameworks (ZIFs), as a 
      subfamily of metal-organic frameworks (MOFs), and their unique features, 
      including tunable pore size, large surface area, high thermal stability, and 
      biodegradability/biocompatibility, have made them attractive in the field of 
      biomedicine, especially for drug delivery and biomineralization applications. The 
      high porosity of ZIFs gives them the opportunity for encapsulating a high amount 
      of therapeutic drugs, proteins, imaging cargos, or a combination of them to 
      construct advanced multifunctional drug delivery systems (DDSs) with combined 
      therapeutic and imaging capabilities. This review summarizes recent strategies on 
      the design and fabrication of ZIF-based nansystems and their exploration in the 
      biomedical field. First, recent developments for the adjustment of particle size, 
      functionality, and morphology of ZIFs are discussed, which are important for 
      achieving optimized therapeutic/theranostic nanosystems. Second, recent trends on 
      the application of ZIF nanocarriers for the loading of diverse cargos, including 
      anticancer medicines, antibiotic drugs, enzymes, proteins, photosensitizers, as 
      well as imaging and photothermal agents, are investigated in order to understand 
      how multifunctional DDSs can be designed based on the ZIF nanoparticles to treat 
      different diseases, such as cancer and infection. Finally, prospects on the 
      future research direction and applications of ZIF-based nanomedicines are 
      discussed.
CI  - (c) 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Maleki, Aziz
AU  - Maleki A
AD  - Department of Pharmaceutical Nanotechnology, School of Pharmacy, Zanjan 
      University of Medical Sciences, Zanjan, 45139-56184, Iran.
AD  - Zanjan Pharmaceutical Nanotechnology Research Center (ZPNRC), Zanjan University 
      of Medical Sciences, Zanjan, 45139-56184, Iran.
FAU - Shahbazi, Mohammad-Ali
AU  - Shahbazi MA
AD  - Department of Pharmaceutical Nanotechnology, School of Pharmacy, Zanjan 
      University of Medical Sciences, Zanjan, 45139-56184, Iran.
AD  - Drug Research Program, Division of Pharmaceutical Chemistry and Technology, 
      Faculty of Pharmacy, University of Helsinki, Helsinki, FI-00014, Finland.
FAU - Alinezhad, Vajiheh
AU  - Alinezhad V
AD  - Department of Pharmaceutical Nanotechnology, School of Pharmacy, Zanjan 
      University of Medical Sciences, Zanjan, 45139-56184, Iran.
FAU - Santos, Helder A
AU  - Santos HA
AUID- ORCID: 0000-0001-7850-6309
AD  - Drug Research Program, Division of Pharmaceutical Chemistry and Technology, 
      Faculty of Pharmacy, University of Helsinki, Helsinki, FI-00014, Finland.
AD  - Helsinki Institute of Life Sciences, HiLIFE, University of Helsinki, Helsinki, 
      FI-00014, Finland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200507
PL  - Germany
TA  - Adv Healthc Mater
JT  - Advanced healthcare materials
JID - 101581613
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Metal-Organic Frameworks)
RN  - 1318-02-1 (Zeolites)
SB  - IM
MH  - Anti-Bacterial Agents/pharmacology
MH  - Biomineralization
MH  - Humans
MH  - *Metal-Organic Frameworks
MH  - *Neoplasms/drug therapy
MH  - *Zeolites
OTO - NOTNLM
OT  - ZIF nanoparticles
OT  - antibacterial therapies
OT  - biomineralization
OT  - cancer therapies
OT  - metal-organic frameworks
EDAT- 2020/05/10 06:00
MHDA- 2021/05/11 06:00
CRDT- 2020/05/09 06:00
PHST- 2020/02/14 00:00 [received]
PHST- 2020/03/25 00:00 [revised]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2021/05/11 06:00 [medline]
PHST- 2020/05/09 06:00 [entrez]
AID - 10.1002/adhm.202000248 [doi]
PST - ppublish
SO  - Adv Healthc Mater. 2020 Jun;9(12):e2000248. doi: 10.1002/adhm.202000248. Epub 
      2020 May 7.